Search

Displaying results 5711 - 5720 of 9322 in total
  1. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

  2. Drug

    Muparfostat

    go.drugbank.com/drugs/DB05808
    Investigational

    Muparfostat (PI-88) is a mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic

  3. Drug

    Calusterone

    go.drugbank.com/drugs/DB01564
    ExperimentalIllicit

    A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.

  4. Drug

    SLx-4090

    go.drugbank.com/drugs/DB05678
    Investigational

    SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes. [A33218]

  5. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.

  6. Drug

    Lactobacillus coryniformis K8

    go.drugbank.com/drugs/DB15733
    Experimental

    Lactobacillus is a common bacteria found in the gut with Lactobacillus coryniformis K8 being originally isolated from artisan goat cheese.

  7. Drug

    Stamulumab

    go.drugbank.com/drugs/DB05915
    Investigational

    MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.

  8. Drug

    Osemozotan

    go.drugbank.com/drugs/DB05339
    Experimental

    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)

  9. Drug

    Tesevatinib

    go.drugbank.com/drugs/DB11973
    Investigational

    Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. … In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.

  10. Drug

    Echinacoside

    go.drugbank.com/drugs/DB15488
    Investigational

    [A184577] Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.[A184592] … Echinacoside is a phenylethanoid glycoside isolated from _Echinacea angustifolia_ in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis,